Pharma

Your Article Summary

See Latest Articles

Novartis successfully demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine
Novartis, 06/15/09

Novartis has successfully completed the production of the first batch of influenza A(H1N1) vaccine, weeks ahead of expectations. Cell-based manufacturing technology allows vaccine production to be initiated once a pandemic virus strain is identified without the need to adapt the virus strain to grow in eggs, as with traditional vaccine technologies. This advance has cut weeks off the time required to begin vaccine production. This first batch of ten liters of wild type influenza A(H1N1) vaccine monobulk will be used for pre-clinical evaluation and testing and is also being considered for use in clinical trials.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Important progress in treatment of early and late stage breast cancer with Herceptin, Avastin and T-DM1
Roche, 12/10/09

Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

 See all of Research & Development